Inflagic 5ml contains the active ingredients Dexchlorpheniramine maleate and Betamethasone. Adhering to the prescribed dosage of Inflagic 5ml will enhance therapeutic efficacy and mitigate unwanted side effects.
1. Indications of Inflagic
The Betamethasone component is a synthetic medication belonging to the Glucocorticoid class, characterized by its significant anti-inflammatory effects and embodying the full features of a Glucocorticoid. Betamethasone exerts direct influence on the biosynthesis of Prostaglandins, thereby alleviating pain associated with musculoskeletal disorders.
The Dexchlorpheniramine component is classified as a first-generation antihistamine. Dexchlorpheniramine possesses anticholinergic properties and prevents excessive histamine release by the patient's body. Currently, Dexchlorpheniramine is utilized in the management of allergic conditions such as dermatological allergies, allergic rhinitis, and contact allergies. Notably, Dexchlorpheniramine can penetrate the blood-brain barrier, potentially resulting in sedation or drowsiness in users.
The combination of Betamethasone and Dexchlorpheniramine in Inflagic 5ml is designed to provide both anti-inflammatory and strong anti-allergic effects while reducing edema.
2. Indications for the Use of Inflagic 5ml
Inflagic 5ml is indicated for the following conditions:
- Individuals with respiratory allergies such as allergic rhinitis and severe bronchial asthma.
- Individuals with skin allergies such as serum sickness, chronic urticaria, atopic dermatitis, or allergic contact dermatitis.
- Individuals with ocular allergies including non-granulomatous uveitis, keratitis, conjunctivitis, endophthalmitis, suppurative iritis, and choroiditis.
3. Contraindications for Inflagic 5ml
Inflagic 5 ml is contraindicated in the presence of:
- Allergy or hypersensitivity to any ingredient in the formulation.
- Active viral infections (including psoriasis, herpes simplex, herpes zoster, or hepatitis).
- Uncontrolled psychiatric states.
- Recent live vaccine administration.
- Individuals at risk for narrow-angle glaucoma.
- Individuals at risk of fluid retention due to urinary tract dysfunction.
4. Dosage and Administration of Inflagic 5ml
Administration: Inflagic 5ml is administered orally and can be taken before or after meals.
Dosage:
- For adults and children over 12 years: 1-2 vials per dose, twice daily.
- For children aged 2 to 12 years: 1 vial per dose, 1-2 times daily.
Management of Missed Dose and Overdose of Inflagic 5ml:
- In the event of a missed dose, it should be taken as soon as possible. However, if the next scheduled dose is imminent, the missed dose should be skipped, and only the next dose taken.
- In cases of overdose, acute toxicity or death may occur. Patients should discontinue the medication immediately and seek timely medical intervention.
5. Adverse Reactions of Inflagic 5ml
Patients using Inflagic 5ml may experience the following adverse reactions:
- Common: Hypokalemia, edema, hypertension, Cushing’s syndrome, menstrual irregularities, impaired carbohydrate tolerance, decreased ACTH secretion, avascular necrosis, adrenal atrophy, reversible muscle atrophy, myasthenia, vertebral fracture, osteoporosis, erythema, hirsutism, gastric or duodenal ulcers, hemorrhagic ulcers, acute pancreatitis, insomnia, irregular menstruation.
- Rare: Hypersensitivity, anaphylaxis, weight gain, nausea, hiccups, aseptic abscess, leukocytosis or thromboembolic events...
- Sudden discontinuation of Inflagic 5ml may lead to hypotension, acute adrenal insufficiency, or death.
If any of these symptoms occur, patients should stop using Inflagic 5ml and notify their physician or pharmacist for appropriate management.
6. Drug Interactions of Inflagic 5ml
Inflagic 5ml may cause drug interactions when used concurrently with:
- Barbiturates, aminoglutethimide, phenytoin, rifampicin, ephedrine, and carbamazepine.
- Hypoglycemic agents, diuretics, antihypertensives.
- Acetazolamide or thiazide diuretics.
- Coumarin derivatives.
- Salicylates.
- Monoamine oxidase inhibitors (MAOIs).
- Tricyclic antidepressants, barbiturates.
- Central nervous system depressants.
- Oral anticoagulants.
To ensure safety and effectiveness, patients are advised to inform their healthcare provider about all medications, dietary supplements, and comorbid conditions they may have.
7. Precautions for the Use of Inflagic 5ml and Storage Guidelines
- Caution is advised when administering Inflagic 5ml to individuals engaged in operating vehicles or machinery.
- Caution should be exercised when administering Inflagic 5ml to individuals with a personal or family history of allergies.
- Caution is warranted when using Inflagic 5ml in patients with severe renal or hepatic impairment.
- Caution should be taken when administering Inflagic 5ml to elderly patients, those with poor nutritional intake, or those experiencing cachexia.
- Precaution should be observed when administering Inflagic 5ml to pregnant or lactating women.
- It is imperative to avoid use of Inflagic 5ml if there are signs of color change, mold, leakage, or expiration.
The aforementioned information regarding Inflagic 5ml is comprehensive; patients are advised to read the usage instructions thoroughly and consult a physician or pharmacist prior to administration. Self-purchasing Inflagic 5ml for home treatment is inadvisable due to the potential for adverse side effects.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
